Parasite variation provides hope for malaria vaccine design.
Taylor-Robinson
A
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000940:Antigenic Variation; D000953:Antigens, Protozoan / Q000276:immunology; D003429:Cross Reactions; D015195:Drug Design; D000939:Epitopes / Q000276:immunology; D004912:Erythrocytes / Q000469:parasitology; D006801:Humans; D017780:Malaria Vaccines; D016778:Malaria, Falciparum / Q000469:parasitology; D010963:Plasmodium falciparum / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000953:Antigens, Protozoan; D000939:Epitopes; D017780:Malaria Vaccines; D015800:Protozoan Proteins; C085731:erythrocyte membrane protein 1, Plasmodium falciparum